CTOs on the Move

BridgeHealth

www.bridgehealth.com

 
BridgeHealth connects people with the nation`s best surgical care for a better experience, better outcomes, and better value. We offer a value-based approach to surgical care for self-insured plan sponsors and their members, saving them an average of 30% to 50% on procedures compared with PPO rates. BridgeHealth`s nationwide Centers of Excellence focus on quality outcomes and provide pre-negotiated bundled case rates for a broad scope of surgical procedures, including musculoskeletal, neurological, general surgery, cardiac, bariatric, and women`s health. BridgeHealth contracts with hospital providers who rank in the top quartile for their clinical specialty, based on outcomes and other objective ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Kris Jamsa
Chief Technology Officer Profile

Funding

BridgeHealth raised $40M on 10/22/2020

Similar Companies

Soda Health

Soda Health is a healthcare technology company focused on building solutions which eliminate health inequities and create a healthier America. Social Determinants of Health (SDOH) have a major impact on health and wellbeing, as well as the cost of care. Our mission is so important, we found a way to work SDOH into our company name.

Wallace Pharma

Wallace Pharma is a Decatur, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Reden and Anders

Reden and Anders Ltd is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Florida Blue

Florida Blue is a subsidiary of a not-for-profit health solutions company dedicated to serving all Floridians in the pursuit of health. Florida Blue is an independent licensee of the Blue Cross and Blue Shield Association, serving residents and businesses in the state of Florida.

PharmaBlock Sciences

PharmaBlock Sciences (Nanjing), Inc. is a leading innovative chemistry products and services provider throughout the pharmaceutical R&D process. Its core businesses include: a catalog of specially designed scaffolds and building blocks; custom synthesis; process development; manufacturing of key intermediates and RSMs; and FTE services. The company was listed on Shenzhen Exchange Stock in China on November 10, 2017. PharmaBlock has rapidly gained recognition for its outstanding capability in the design, synthesis, and supply of lab scale building blocks. Building on that success, the company acquired Shandong Diai Biotechnology Co., Ltd. as its pilot plant and manufacturing site in 2016, and is providing scale-up synthesis and manufacturing of key intermediates/RSMs. PharmaBlock is now committed to a more comprehensive and long-term service to valued customers.